[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sichuan Jishengtang Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100557177","phase-3-phase-3-clinical-trial-of-wujia-yizhi-granules-in-the-treatment-of-mild-to-moderate-alzheimers-dementia-syndrome-of-deficiency-of-spleen-and-kidney-100557177",false,"NCT06534723","Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)","A 12-month Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney).","Inclusion Criteria:\n\n1. Male or female, age range : 50 - 80 years old.\n2. Informed consent signed and dated by patient or legal representative.\n3. The participants are mild-to-moderate AD patients who meet the diagnostic criteria for AD proposed by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2018 and have a disease course of more than 6 months. If participants lack previous pathological evidence or biomarkers of Alzheimer's dementia, they must have evidence of β-amyloid deposition biomarkers during screening (PET with abnormal amyloid deposition or low cerebrospinal fluid Aβ 42 and Aβ 42\u002FAβ 40 ratio).\n4. MMSE score 11 to 26;CDR-GS score 1 to 2 。\n\nExclusion Criteria:\n\n1. Participants with non AD induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed dementia (AD VaD), vascular dementia (VD), Parkinson's disease dementia (PDD), Lewy body dementia (DLB), Huntington's disease related dementia, frontotemporal lobe dementia (FTD), etc; Endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by folate, vitamin B12 deficiency, or any other reason; Existence of consciousness disorders, etc.\n2. Participants have a history of epileptic seizures.\n3. Participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium.\n4. HAMD-17 score ≥ 17 points.\n5. HAMA score ≥ 14 points.\n6. Participants were taking antidepressants, anxieties, and antipsychotic drugs during screening.\n7. HIS score ≥ 4 points..","ALL","50 Years","80 Years",{"count":20,"type":21},570,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia",[27],"Alzheimer's Dementia","RECRUITING","2025-12-25",{"date":31,"type":32},"2025-12-29","ACTUAL",{"date":34,"type":32},"2024-08-20",{"date":36,"type":21},"2026-12-01",{"name":38,"class":39},"Sichuan Jishengtang Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100498580","phase-3-clinical-trial-of-shugan-jieyu-capsule-in-generalized-anxiety-disorder-100498580","NCT05772104","Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder","A Multi-center, Randomized, Double-Blind Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder","Inclusion Criteria:\n\n1. Primary diagnosis of generalized anxiety disorder (GAD) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as confirmed by the MINI at Screening, The duration of illness must be ≥ 6 months；\n2. Age 18-65 years old；\n3. Hamilton Anxiety Rating Scale (HAM-A) Total Score of ≥ 14 at both Screening and Baseline，Anxious Mood (item 1) score ≥2；\n4. Clinical Global Impression of Severity Scale (CGI-S) score of ≥ 3 at both Screening and Baseline\n5. The TCM syndrome is liver Qi stagnation and spleen deficiency syndrome.\n\nExclusion Criteria:\n\n1. Diagnosed with a psychiatric disorder other than GAD that meets DSM-5 criteria within 6 months prior to screening；\n2. Alcohol or drug abuse or dependence in the 6 months prior to screening, or urine positive for multiple drugs combined at screening\n3. Hamilton Depression Rating Scale (HAMD-17) Total Score of \\> 17 at Screening or Baseline，or Depressive Mood (item 1) score ≥2；\n4. Patients with Severe Insomnia.","18 Years","65 Years",{"count":51,"type":21},495,[24],"This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.",[55],"Generalized Anxiety Disorder","2024-12-17",{"date":58,"type":32},"2024-12-18",{"date":60,"type":32},"2023-04-17",{"date":62,"type":21},"2025-06-01",{"name":38,"class":39},""]